Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2017-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic
agent nivolumab given in combination with gamma knife therapy and valproate in patients with
recurrent glioblastoma, a common and lethal type of brain cancer.